Praxis to Highlight Breakthrough Therapy Ulixacaltamide Phase 3 Results with 15 Presentations at AAN 2026
Ulixacaltamide has earned FDA Breakthrough Therapy designation as the first positive Phase 3 Essential3 program in essential tremor and will be highlighted at the AAN 2026 meeting in Chicago, April 18–22. Praxis will deliver 15 scientific presentations—including a plenary on topline Essential3 results—and host an in-booth showcase at booth #2324.
1. Essential3 Phase 3 Program
Ulixacaltamide, a highly selective T-type calcium channel inhibitor, achieved the first positive Phase 3 results in essential tremor’s Essential3 program, demonstrating durable improvements in daily function and earning FDA Breakthrough Therapy designation. These topline findings will be showcased in a plenary session on Maintenance of Response and Durability from the randomized withdrawal study.
2. AAN 2026 Presentation Schedule
At the AAN 2026 meeting in Chicago, April 18–22, Praxis will present 15 scientific sessions, including three oral presentations, 12 posters and a plenary on Essential3 results. An in-booth speaker showcase at booth #2324 will offer detailed discussions on Phase 3 data and the unmet disease burden in essential tremor.
3. Broader CNS Pipeline
Beyond essential tremor, Praxis will share clinical updates on its elsunersen antisense oligonucleotide program for early onset SCN2A developmental and epileptic encephalopathy and present preclinical and clinical posters on predictive seizure models, pain frameworks, precision sodium channel modulators, and Phase 1–3 trials of Vormatrigine and Relutrigine programs.